Cerebral Edema Clinical Trial
Official title:
Molecular Mechanisms Underlying the Occurrence of Malignant Cerebral Edema After Large Hemispheric Infarction (LHI)
The study is to explore the molecular mechanisms underlying the occurrence of malignant cerebral edema (cerebral hernia) after large hemispheric infarction. Acute LHI (<=48h) patients that develop cerebral hernia or not within 5 days post-stroke onset, as well as the healthy controls will be studied. The participants will be followed for up to 6 months post stroke-onset, and their modified Rankin Scale (mRS) will be recorded. A mRS score of 0-4 is considered as a favorable outcome while a score of 5-6 as an unfavorable one.
A total of 80 patients with acute large hemispheric infarction (LHI) within 48h after occurrence admitted into NICU of Xuanwu Hospital as well as 40 healthy volunteers will be recruited. The patients' baseline characteristics, treatment and changes of clinical conditions will be recorded, and ICP monitoring (D2-D7 post-stroke), chest X-ray (D2, D7, D14 post-stroke), ECG (D2, D7, D14 post-stroke), cerebral vascular ultrasound, TCD and head MRI (T1WI, T2WI, FLAIR, DWI) on D2 and D14 post-stroke will be performed. Blood samples from both the LHI patients (D2, D4, D7, and D14 post-stroke) and the controls will be analyzed for NEU, TNF-alpha, IL-1b, IL-6, IL-8, IL-17, ICAM-1, VCAM-1, MPO, NE, MMP-9,miRNA, free dsDNA, H3CIT and NETosis levels. All patients were treated for brain edema with osmotic medications—either intravenous 20% mannitol or 10% hypertonic saline. In addition, some patients were treated with decompressive surgery.The patients will be followed up to 6 months and their modified Rankin Scale (mRS) will be recorded. A mRS score of 0-4 is considered as a favorable outcome while a score of 5-6 as an unfavorable one. Statistical differences in the different parameters between different groups at different time points will be analyzed by SPSS 22.0 software. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT01954290 -
Study of Stroke Related Edema Treatments
|
Phase 2 | |
Terminated |
NCT00243022 -
Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme
|
Phase 2 | |
Recruiting |
NCT05585255 -
Clinical Significance of DKK2 Protein in Cerebral Ischemia-reperfusion Injury
|
||
Completed |
NCT04116138 -
Antisecretory Factor in Primary Glioblastoma 1
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT05725694 -
Acute Ischaemic STROKE: From LAboratory to the Patient's BED
|
||
Withdrawn |
NCT03330704 -
Small-Volume, Patient-Specific, Balanced Hypertonic Fluid Protocol Validation
|
Early Phase 1 | |
Completed |
NCT01365793 -
Randomized Control Trial of Fluid Therapy for Pediatric Diabetic Ketoacidosis
|
Phase 3 | |
Completed |
NCT03000283 -
Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study
|
Phase 1 | |
Active, not recruiting |
NCT06018545 -
AI Assisted Reader Evaluation in Acute Computed Tomography (CT) Head Interpretation
|
||
Completed |
NCT05796349 -
Study on Data Acquisition and Image Characteristics of Brain Multifrequency EIT in Healthy People and Patients With Brain Diseases
|
||
Recruiting |
NCT04303065 -
Dexamethasone for the Treatment of Vasogenic Pericontusional Edema.
|
Phase 3 | |
Withdrawn |
NCT01605357 -
Hypernatremia for the Prevention and Treatment of Cerebral Edema in Traumatic Brain Injury
|
Phase 1/Phase 2 | |
Recruiting |
NCT04247659 -
Study on the Relationship Between Asymmetric Vascular Sign of Cortex and Prognosis in Massive Cerebral Infarction
|
Phase 4 | |
Completed |
NCT05060159 -
Conventional Hemodialysis Versus Post-Dilution Hemofiltration in Incident RRT
|
N/A | |
Completed |
NCT01060969 -
Tadalafil and Acetazolamide Versus Acetazolamide in Acute Mountain Sickness Prevention
|
N/A | |
Completed |
NCT05200728 -
The Tolerability, Safety, and PK Characteristics of SIM1910-09 in Healthy Chinese Volunteers
|
Phase 1 | |
Withdrawn |
NCT03409237 -
Coagulation Activation by Hyperosmolar Agents in Intracranial Hypertension
|
||
Not yet recruiting |
NCT06096415 -
Safety and Efficacy of ABX-101 in Participants Aged 18 to 50 Years of Age With Moderate to Severe Traumatic Brain Injury
|
Phase 2 | |
Completed |
NCT02142712 -
Histamine Glutamate Antagonism in Stroke
|
Phase 2 | |
Active, not recruiting |
NCT04088630 -
Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage
|
Early Phase 1 |